

Solidarité
avec les Autoimmunologistes d'Ukraine





ETAT ACTUEL DE LA RECHERCHE DES AUTOANTICORPS


René-Louis Humbel

RECHERCHE DES AUTOANTICORPS

METHODES

IMMUNOFLUORESCENCE


Cellules en Culture
Cellules Isolées
Cellules transfectées
Tissus d'organes spécifiques



IMMUNOESSAIS

Réaction avec des
Antigènes Immobilisés

ELISA
IMMUNODOTS (LIA)
ALBIA/PMAT/PACIA





ANTICORPS

Sélectivité
Isotypes
Avidité

ANTI-Ig

Spécificité
Marquage

MESURE


ANTIGENE

Origine
Nature, Pureté
Structure
Mélanges
IMMOBILISATION
Conformation
Epitopes



REACTION

Milieu/Solvant
Composition
pH, Force Ionique
Température
Temps de Réaction




Colorimétrie
Fluorescence

Luminométrie

 CHIMILUMINESCENCE


ANTICORPS ANTI-CHROMATINE



ANTI-NUCLEOSOMES

A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation

Bernard J Fox,¹ Jason Hockley,² Peter Rigsby,² Carl Dolman,¹ Pier Luigi Meroni,³ and Johan Rönnelid⁴




Anti-dsDNA-NcX ELISA (IgG)

Test instruction

Principles of the test: The ELISA test kit provides a semiquantitative or quantitative *in vitro* assay for human autoantibodies of the IgG class against double-stranded, genomic DNA (dsDNA) in serum.


The Anti-dsDNA-NcX ELISA microtiter plates (Nunc, Roskilde, Denmark) were coated at 4°C first with a 0.1 µg/ml concentration of an ultrapure nucleosome preparation from calf thymus (free of Scl-70, histone H1 and other nonhistone components) [18] in sodium carbonate buffer for 3 hours, followed by a 1.5 µg/ml concentration of highly purified, native dsDNA isolated from calf thymus in sodium carbonate buffer overnight.

ANTI-DNA WO 15/174



QUANTA Flash® RNP

Native purified RNP is coated on to paramagnetic beads,



The natural U1-RNP antigen, however, contains not only epitopes or antibody binding sites that are unique to U1 RNP, but it also contains the Sm antigens; consequently, the patient antibody response against isolated Sm antigens must be considered when reporting out anti-RNP results.

ACPA


ANTICORPS ANTI-PROTEINES CITRULLINES

| | |
|--------------------|--|
| ANTI- CCP2 | Cyclic Citrullinated Peptide 2 |
| CCP3 | Cyclic Citrullinated Peptide 3 |
| CPA | Citrullinated Rat Filagrin |
| Sa | Citrullinated MBP |
| MCV | Citrullinated Mutated Vimentin |
| hsCCP | idem CMV |
| CEP1 | α Enolase |
| <i>CFIB</i> | <i>Citrullinated Fibrinogen</i> |


ACPA

ANTI-CITRULLINATED PROTEIN ANTIBODIES

- CCP2** Peptides Synthétiques 2
- CCP3** Peptides Synthétiques 3
- MCV** Vimentine Mutée Citrul.



ANTICORPS ANTI-TIF-1



D TEK DOT

: TIF-1 γ rec. HEK293

EUROIMMUN DOT

: TIF-1 γ rec. Ecoli

IMMCO DOT

: TIF-1 α rec.

MBL ELISA

: TIF-1 γ rec. Sf9

PMAT INOVA


: TIF-1 γ

ANTICORPS ANTI-Th/To

**LIA
EUROIMMUN**


*Mecoli 2021
IP 109 patients*

| | |
|--------------------|-------------|
| hPOP1 | 93 % |
| Rpp38 | 89 % |
| Rpp30 | 69 % |
| Rpp25 | 60 % |
| Any Subunit | 92 % |



Antibodies against neo-epitope tTg complexed to gliadin are different and more reliable than anti-tTg for the diagnosis of pediatric celiac disease

Aaron Lerner^{a,b,*}, Patricia Jeremias^a, Sandra Neidhöfer^a, Torsten Matthias^a




ANTI-SSA/Ro et ANTI-Ro52

INOVA QUANTA Lite SS-A is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of SS-A (60kDa and 52kDa) antibodies in human serum.

EliA[™] For determination of SS-A/Ro antibodies


Antigen: human recombinant SS-A/Ro (60 kDa, 52 kDa) proteins

AESKULISA SS-A is a solid phase enzyme immunoassay for the quantitative and qualitative detection of antibodies against Ro/ SS-A in human serum. The assay employs human Ro/SS-A antigen composed of highly purified native 60kDa and recombinant human 52 kDa Ro/SS-A protein.



ASSOCIATION SSA/Ro60 et Ro52


ANTIBODIES TO SSA/Ro60 and Ro52



| | SLE 32 | SLE 55 | SSc 85 | Myositis48 |
|-------------|--------|--------|--------|------------|
| Ro52 | 3.2 | 0.6 | 3.7 | 2.4 |
| Ro60 (SS-A) | 1.1 | 2.1 | 0.6 | 2.8 |
| Mixture | 0.4 | 0.7 | 0.6 | 0.8 |

Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody

IPAF


A. Sclafani^{1*} , K. M. D'Silva², B. P. Little³, E. M. Miloslavsky², J. J. Locascio⁴, A. Sharma³ and S. B. Montesi¹

73 patients with ILD and Ro52


| | <i>ELISA Ro52</i> | <i>ELISA SSA Mix</i> |
|-------------------------------|-------------------|----------------------|
| Ro52 isolated (no SSA60/ENA): | 50 (68%) | 44 (60%) |
| Ro52 + Myositis Spec.Ab: | : 23 (32%) | 19 (14%) |
| IPAF criteria : | : 49 % | 30.1 % |

ANTICORPS ANTI- β 2 GLYCOPROTEINE 1

 *Epitope G39-R43*





β 2 GP1
Phase Liquide




ANTICORPS ANTI-PR3


Mr.Gr. Maladie de Wegener




Ancor ELISA



Capture ELISA



Direct ELISA



PR3 DOT